Sen. Grassley’s letter to Amgen regarding FDA access to study data and rebate payments and discounts to physicians
Via Electronic Transmission
Mr. Kevin Sharer Chief Executive Officer Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799
Dear Mr. Sharer:
The United States Senate Committee on Finance (Committee) has jurisdiction over the Medicare and Medicaid programs and, accordingly, a responsibility to the more than 80 million Americans who receive health care coverage under those programs to oversee the proper administration of the programs, including the payment for prescription drugs regulated by the Food and Drug Administration (FDA).
Thank you for the briefing that Amgen Inc. (Amgen) provided my Committee staff on May 24, 2007, in response to my letter to you dated May 16, 2007. Additionally, thank you for your cooperation with the Committee’s request for information related to erythropoiesis-stimulating agents (ESAs).
###
Next Article Previous Article
Recent News
- Wyden Blasts Trump Tariffs on Brazilian Beef, Coffee and Building Materials to Protect Brazil’s Corrupt Ex-President
- Wyden Blasts Trump Tariff Letters: ‘More Trade Taxes, Higher Prices, More Uncertainty.’
- Wyden to USTR: Congress Must Approve Binding Trade Deals
- Wyden, Warren, Gillibrand, and Sanders Demand Answers on Reckless Rollout of AI Tools at Social Security
- Wyden Condemns Passage of Cruel Senate Republican Budget